Dry sustained release theophylline oral formulation

Details Dry sustained release theophylline oral formulation Dry sustained release theophylline oral formulation

1987-05-18

1988-11-22

Lusignan, Michael

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

424491, 424494, 514263, 514962, 514964, A61K 916

Patent

active

047865091

ABSTRACT:
A sustained release theophylline containing oral dosage formulation comprising theophylline containing micropellets coated with from about 0.5% to about 2% by weight of a pharmaceutically acceptable water-insoluble film former, preferably ethyl cellulose and having first order release. The formulation is an improvement over theophylline containing micropellets coated with two film formers which have zero order release. The oral dosage formulation has superior non-fasting release and absorption characteristics when compared to the zero order release formulation.

REFERENCES:
patent: 3835221 (1974-09-01), Fulberth et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4587118 (1986-05-01), Hsiao
patent: 4692337 (1987-09-01), Ukigayo et al.
Pedersen et al., Pediatrics, vol. 74, No. 4, pp. 534-538, (1984).

Affiliated with

Also associated with

Rating

Dry sustained release theophylline oral formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dry sustained release theophylline oral formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dry sustained release theophylline oral formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-434417